Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Glandular and Epithelial

Explore clinical trials studying Neoplasms, Glandular and Epithelial. Study availability and eligibility vary by location and protocol.

12,664 public trials 2,917 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Glandular and Epithelial trial results

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797

Conditions
Adenocarcinoma, Adnexal Diseases, Biliary Tract Diseases, +52 more
Locations
  • Precision NextGen Oncology & Research Center Beverly Hills, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • University of California Los Angeles Rheumatology Westwood, Los Angeles, California, United States
  • Norwalk Hospital Norwalk, Connecticut, United States
View all 70 locations
View Trial Details
Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Alaska Oncology and Hematology ( Site 0133) Anchorage, Alaska, United States
  • Providence Medical Foundation ( Site 0141) Fullerton, California, United States
  • Cedars-Sinai Medical Center ( Site 0112) Los Angeles, California, United States
  • New England Cancer Specialists ( Site 0132) Westbrook, Maine, United States
View all 124 locations
View Trial Details
Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +32 more
Locations
  • Children's Hospital Los Angeles ( Site 1006) Los Angeles, California, United States
  • Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) Aurora, Colorado, United States
  • Yale New Haven Hospital ( Site 1012) New Haven, Connecticut, United States
  • Johns Hopkins All Children's Hospital ( Site 1025) St. Petersburg, Florida, United States
View all 71 locations
View Trial Details
Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University Cancer and Blood Center LLC Athens, Georgia, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • Saint Alphonsus Cancer Care Center-Boise Boise, Idaho, United States
View all 137 locations
View Trial Details
Recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

NCT06589804

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +38 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Fremont - Rideout Cancer Center Marysville, California, United States
  • VA Palo Alto Health Care System Palo Alto, California, United States
  • UCHealth Memorial Hospital Central Colorado Springs, Colorado, United States
View all 192 locations
View Trial Details
Recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

NCT06184750

Conditions
Adenocarcinoma, Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, +17 more
Locations
  • University of Arizona Cancer Center - Prevention Research Clinic Tucson, Arizona, United States
  • Northwestern University Chicago, Illinois, United States
  • University of Illinois College of Medicine - Chicago Chicago, Illinois, United States
  • University of Kansas Cancer Center Kansas City, Kansas, United States
View Trial Details
Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069

Conditions
Adnexal Diseases, Advanced Solid Tumor, Bladder Cancer, +72 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California, San Diego (UCSD) - Moores Cancer Center La Jolla, California, United States
  • UCLA Department of Medicine-Hematology/Oncology Los Angeles, California, United States
  • Sarah Cannon Research Institute at HealthOne Denver, Colorado, United States
View all 38 locations
View Trial Details
Recruiting

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

NCT07607769

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Research site Ancona, Italy
  • Research Site Ancona, Italy
  • Research Site Bergamo, Italy
  • Research site Foggia, Italy
View all 24 locations
View Trial Details

Related conditions